Olema Pharmaceuticals Inc., a company looking to improve on current endocrine therapies with an oral estrogen receptor antagonist and degrader of its own, has filed for a $170 million IPO on Nasdaq. The offering follows an $87.4 million series C round, closed in September and a $54 million series B financing closed not long before in July.
Biopharmas raising money in public or private financings, including: Bioatla, Compass, Intervenn, Kinnate, Moberg, Nereid, Oncozenge, Sigilon, Stat Codon.
HONG KONG – Kira Pharmaceuticals is riding high after completing a $46 million fundraiser and appointing Frederick Beddingfield as CEO. “The $46 million comprises a series A of $18 million and a series B of $26 million, with investors Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital participating in both rounds,” Beddingfield told BioWorld.
LONDON – Synendos Therapeutics AG is poised for a fresh attempt at drugging the endogenous endocannabinoid system after raising CHF20 million (US$21.8 million) to take its lead program into clinical development.
TORONTO – Biomaterials med-tech company 3D Biofibr Inc. has raised CA$550,000 (US$423,500) seed funding to develop, commercialize and scale up a biofilm platform that mimics the spinning behavior of the common spider.
Though founded in 2018, Inipharm Inc. has just closed on a $35 million series A financing designed to push its lead program through an IND filing and into the clinic to treat liver-related diseases.
RSS
